WellStar Cancer Network 2016 Annual Report

WELLSTAR CANCER NETWORK • 2016 ANNUAL REPORT • #

2016 Cancer Annual Report 

(Based on CY 2015 Program Activity) 

Welcome to the WellStar Cancer Network 2016 Annual 

Report based on 2015 program activities. 2015 was a year 

of transformative growth throughout our health system, and a 

year in which our hard work yielded the most important kind of 

results: improved outcomes and improvements in our patients’ 

quality of life. 

During this year we saw the results of an $11 million redesign 

of our Cancer Center at WellStar Kennestone Hospital and 

opened the doors to several new facilities that together will 

propel WellStar into a top-tier national cancer program. These 

include our new state-of the-art 6,600 square-foot outpatient 

infusion center, the Center for Survivorship and Support, and a 

Patient Resource Center unlike any other in the United States. 

All of these improvements were developed with a singular 

focus on the patient experience. 

Medicine at WellStar also achieved top tier results. Our 

multidisciplinary STAT Clinics drastically reduced the number 

of days from initial diagnosis to initial treatment for certain 

cancers – resulting in less time spent worrying and waiting, 

and more time treating cancer. Our commitment to increased 

lung cancer screening saw a major shift in identifying lung 

cancers at earlier, more treatable, stages than ever before. 

Our expanded Cancer Genetics program had its busiest year 

ever in 2015, and is projected to see even more patients in 2016. 

In addition to expanded medical options and major capital 

improvements, WellStar maintained its leading role in bringing 

national resources to our community setting. We are still the only 

hospital system in Georgia to partner with Accuray to offer the 

company’s CyberKnife ® and TomoTherapy ® platforms. These 

state-of-the-art technologies let us treat difficult and otherwise 

untreatable cancers with superior precision and reduced treatment 

time. We also continue to be the only health system in Metro 

Atlanta to participate in the Mayo Clinic Care Network, through 

which WellStar clinicians can consult with Mayo Clinic Care 

Network experts on complex cases at no cost to our patients. 

WellStar believes that collaboration with other leading 

organizations is essential to achieving the best patient outcomes. 

In 2015, we launched a first-in-the-nation partnership with the 

American Cancer Society to provide a new resource center where 

patients and family members can learn about their diagnosis 

and treatment options. Right next door, specially trained nurse 

navigators can offer guidance to those seeking information from 

our abundant in-house and online libraries. 

Advances in treatment, technology and infrastructure are 

important pieces in WellStar’s ultimate goal: healing people. 

But the most essential element is our people. We deliver 

exceptional cancer care because WellStar is the sum of our 

physicians, nurses, administrators, managers, therapists, 

other professionals and volunteers who work collaboratively 

to ensure that our patients are given the best chance at a 

good long-term outcome. 

Across WellStar’s campuses, oncologists, surgeons, radiation 

oncologists, infusion specialists, nurses and counselors treat 

more than 3,500 new cancer cases each year. In addition to the 

latest technologies, access to clinical trials and expert physicians, 

patients also can learn about the best nutrition strategies, receive 

spiritual support, and manage the physical side effects of cancer 

treatment. We treat people from diagnosis through survivorship, 

offering an environment unlike any other. 

As much as we are honored by the distinction, we were not 

surprised when our cancer program was recognized recently as 

2 • WELLSTAR CANCER NETWORK • 2016 ANNUAL REPORT

one of the top programs in the country on Becker’s Hospital 

Review’s “100 Hospitals and Health Systems with Great 

Oncology Programs.” With our major infrastructure upgrades, 

innovative holistic services, and the strength and expertise of 

our professional team, we anticipate many more such honors in 

the years to come. 

In 2015, we made great strides toward our goal of achieving 

the best of both worlds: world-class cancer care in a community 

setting. Thank you for your ongoing support of the WellStar 

Cancer Network. 

Respectfully, 

Michael B. Andrews, M.D. 

Chief Cancer Officer 

David L. Parks, M.D. 

Cancer Committee Chairman 

WELLSTAR CANCER NETWORK • 2016 ANNUAL REPORT • 3

Investments in Cancer 

“It is wonderful how much may be done, if we are always doing.” - Thomas Jefferson 

IIt takes an extraordinary effort to achieve 

an extraordinary outcome. WellStar provides 

cancer care that extends beyond medicine. 

We treat the psychosocial, spiritual and 

ancillary physical needs that frequently 

attend cancer, and deliver care in the most 

efficient manner possible, reducing wait 

times and consolidating services wherever 

possible. With this in mind, we have 

developed a range of programs and services 

that address the needs of Mind, Body and 

Spirit for patients currently in treatment and 

those who have completed treatment. 

In 2015, we saw the culmination of years 

of effort and an $11 million investment 

when we opened the doors to a dedicated 

center for these programs and services at 

our Kennestone Campus: the new Center 

For Survivorship and Support. This center 

is a hub for healing - providing support to 

patients and their caregivers - and aiding 

the growing number of cancer survivors 

in our community as they adjust to life 

after cancer treatment. These services are 

provided in an atmosphere emphasizing 

dignity, respect and collaborative decision 

making. 

Individual program and service offerings are 

constantly evolving, and our commitment to 

patient and family-centered care will only 

grow in coming years. 

Offerings that address the needs 

of the mind include: 

• Parks Resource Library 

• Mindfulness-based stress 

reduction sessions 


of the body include: 

• Manning Wellness Kitchen - a new 

state-of-the-art demonstration kitchen 

for nutritional education 

• Wellness Shoppe offering wig and 

accessory options for those experiencing 

hair loss 

• Bra and mastectomy prosthesis services 

• Yoga, tai chi and acupuncture 

for fitness and stress relief 


of the spirit include: 

• Gray Chapel - a tranquil chapel where 

patients and their families can seek 

and renew their spiritual strength. 

Chaplains provide meditation services 

here twice each week. 

• Newly renovated Garden of Courage – 

a space for peaceful reflection and 

joyous celebration when patients 

triumphantly ring the bell upon 

completion of their final treatment. 

(Clockwise) Manning Wellness Kitchen; 

Wellness Shoppe; Parks Resource Library; 

Rick Gray Family Chapel 


IMPROVING ACCESS 

Cancer is complex, and although there has 

never been more knowledge about it than 

the present, learning and making decisions 

about a disease with which you or a loved 

one has recently been diagnosed can be 

quite overwhelming. Information about a 

specific disease or course of treatment can 

be hard to find. In 2015, WellStar addressed 

this challenge in several ways. Most visible 

among our efforts to improve access to care 

and information was the WellStar Cancer 

Connect Line, a one-stop phone line where 

patients can learn about WellStar Cancer 

Network services and be connected directly 

to a nurse navigator to plan next steps. 

CENTER FOR GENETICS AND 

INDIVIDUALIZED MEDICINE 

WellStar’s commitment to improving 

access to information about cancer 

includes information about individual risk 

for hereditary cancers. Between five and 

ten percent of all cancers are diagnosed 

in people with an inherited predisposition 

toward increased risk. Through WellStar’s 

Genetic Risk Assessment, when possible, 

we strike at cancer before it appears. 

Our patients first meet 

with a genetic counselor 

to determine whether 

and which genetic 

testing is appropriate. 

If it is, the patient will 

receive genetic testing 

for the specific hereditary conditions that 

are known to increase the risk of various 

cancers. We then recommend specific 

courses of action based on the results, 

ranging from increased screenings to 

lifestyle changes, all the way to prophylactic 

medication and procedures. Each patient 

receives an individualized plan giving him 

or her the best chance for prevention and 

early detection. 

Having this knowledge contributes to 

smart and effective decisions about early 

detection, risk reduction and treatment if 

it is needed. All of these are essential to 

achieving the best outcome. While WellStar 

already operates the highest volume cancer 

genetics program in the state of Georgia, in 

2015 we greatly increased the availability of 

genetic counseling and testing as part of our 

comprehensive cancer care. 

This year WellStar opened the new Center 

for Genetics and Individualized Medicine as 

part of the newly renovated Cancer Center 

at Kennestone Hospital. The space was 

built to support the growth of our genetics 

program and enhance the experience of our 

genetic counseling patients. An additional 

genetic counselor position was added in 

2015, allowing the already bustling program 

to have its busiest year ever. In fiscal year 

2016, the program will see 44% more 

patients than the prior year, for a total of 

over 3,000 patients served. 

The Center for Genetics and Individualized 

Medicine includes four custom-designed 

consultation rooms which include video 

monitors that allow patients an innovative 

way to view their family history and review 

complicated data and testing options with 

our genetic counselors. The center has an 

in-house lab to ensure quick and efficient 

collection of patient specimens during their 

appointments. Additional staff has also been 

added to support the increased number of 

patients seen. 


Technology 

CYBERKNIFE ® 

A pain-free, non-surgical option for patients 

with inoperable or surgically complex tumors. 

WellStar is home to Georgia’s first 

CyberKnife Robotic Radiosurgery System. 

This state-of-the-art treatment allows the 

physician to deliver an intense amount of 

radiation at the exact site of the tumor while 

reducing the negative impact on surrounding 

healthy tissue. 

During treatment, multiple beams of highenergy 

radiation converge precisely at the 

targeted point of treatment, usually a tumor 

or lesion inside the body. CyberKnife is 

composed of a linear accelerator (or Linac), 

which is mounted on a robotic arm and 

utilizes a revolutionary image guidance 

system. The flexibility of the robotic arm 

allows CyberKnife to deliver radiation 

to tumors anywhere in the body without 

incisions or scarring, and with minimal side 

effects. The advanced imaging tracks tumors 

and patient movement and will adjust the 

beams of high-dose radiation to ensure 

treatment is delivered with a high degree 

of accuracy. This eliminates the need for 

patients to have stabilizing head frames or 

limit their breathing during treatment to 

minimize movement of the tumor. 

In 2015, Mark McLaughlin, M.D., with other 

WellStar radiation oncologists, performed 

955 treatments, making WellStar one of the 

most active CyberKnife centers in the U.S. 

2015 CyberKnife Treatment Sites 

Brain: 92, Lung: 91, Spine: 24, Benign: 20, Head & Neck: 9, Prostate: 8, Bone: 6, 

GYN: 5, Liver: 4, Rectal: 4, Abdomen: 3, Adrenal: 3, Breast: 1, Kidney: 1, Skin: 1 

Breast-0% 

Skin-0% 

Bone-2% 

Head & Neck-3% 

Benign-7% 

Spine-9% 

Adrenal-1% 

Liver-2% 

Kidney-0% 

Abdomen-1% 

GYN-2% 

Rectal-2% 

Prostate-3% 

Lung-34% 

Brain-34% 


2015 TomoTherapy Treatment Sites 

(2,811 total treatments) 

Prostate: 33, Head & Neck: 19, Brain: 12, GYN: 12, Lung: 8, Bone: 6, 

Breast: 5, Rectal: 5, Esophagus: 3, Pancreas: 1, Skin: 1, Stomach: 1 

Stomach-1% 

Skin-1% Pancreas-1% 

Breast-5% 

Esophagus-3% 

Brain-12% 

Prostate-33% 

Lung-8% 

GYN-12% 

Head & Neck 

-19% 

Anal/ 

Rectum-5% 

TOMOTHERAPY ® 

A pain-free, customized radiation therapy 

system based on individual patient anatomy. 

WellStar is one of the first hospitals in 

Georgia to offer this revolutionary therapy 

and the first to offer patients both CyberKnife 

and TomoTherapy radiation options. 

TomoTherapy combines an advanced form of 

intensity modulated radiation therapy (IMRT), 

with the accuracy of CT scanning, in a single 

machine. This personalized treatment system 

is designed to revolve 360 degrees around 

the patient while taking a CT scan before 

each treatment, verifying the exact position 

of the tumor and, if necessary, adjust the 

beams to ensure precise dosage to the 

tumor. This allows treatment to be delivered 

continuously to the tumor from every angle. 

More beam directions give physicians more 

control in treatment planning, which reduces 

the risk of short- and long-term side effects. 


BRACHYTHERAPY: 

HDR (High-Dose Radiation) 

or LDR (Low-Dose Radiation) 

An internal radiotherapy delivered in a short 

treatment period allowing patients to get 

back to their everyday life sooner. 

WellStar is home to the first Elekta Flexitron ® 

HDR unit in the U.S. and is a reference 

training site to share best practices with other 

radiation centers. Brachytherapy is a type 

of radiotherapy that places the radioactive 

seeds or source in, or at, the tumor site. 

This approach allows a precise treatment 

to the tumor while reducing the risk of 

damage to healthy tissue and organs close 

by. Brachytherapy can be administered as a 

primary treatment course or in combination 

with other treatment methods, such as 

surgery or traditional radiotherapy. 

The HDR approach delivers the dose by a 

radioactive source that is placed temporarily 

in or close to the tumor and removed after 

a few minutes. This treatment method is 

minimally invasive and can be delivered over 

one to 10 treatments. 

The LDR approach is permanent by placing 

tiny radioactive seeds directly into the tumor. 

The seeds deliver low doses of radiation over 

a few months, killing the cancer cells. 

In 2015, WellStar delivered 885 HDR 

Brachytherapy treatments with seven 

patients having LDR Brachytherapy with 

447 radioactive seeds implanted. 

2015 HDR Treatment Sites 

Breast: 71, GYN: 41, Skin: 3, Lung: 3, Esophagus:1 

Lung-3% 

Esophagus-1% 

GYN-34% 

Breast-60% 

Skin-2% 

PRECISION MEDICINE: 

Cancer therapy is always evolving. Physicians 

at WellStar have been closely involved 

with this ongoing progress through clinical 

research trials testing many of the drugs that 

subsequently have become FDA approved. 

At WellStar we use a precision approach 

to treating localized cancers, employing 

state-of-the-art surgeries and radiation 

therapy including IMRT, CyberKnife and 

TomoTherapy. Cancer throughout the body is 

treated with chemotherapy, cell signaling pills, 

immune-based therapies and genetic-based 

therapies. Often, it can be helpful to obtain a 

tissue sample and perform genetic profiling, 

which allows the identification of cancers with 

targetable mutations. A number of cancer 

pills have been created that target specific 

genetic mutations, enabling high response 

rates and improved symptoms. Some genetic 

driver mutations we treat include EGFR, 

ALK, ROS1, BRAF, MET, HER2, RET. In many 

instances, response rates are so high that 

genetic-based therapies have moved ahead 

of chemotherapy as the first line of treatment. 


A PATIENT’S STORY 

The Genetic Risk Assessment program has 

produced many success stories, including 

among our own team members. Desiree 

Meeks, RN is a perioperative charge nurse 

who has worked for WellStar for the last ten 

years. As she says, “Cancer diagnoses are as 

common in my family as cuts and scrapes are 

in other families.” 

Over the years, her aunts, cousins and 

other relatives have been diagnosed with 

ovarian, colorectal and endometrial cancer; 

and she was instrumental in recognizing her 

own mother's cancer. “When I was a recent 

nursing school graduate and my mother 

was 48, I noticed unusual behaviors and 

symptoms in her,” said Ms. Meeks. “She went 

to a doctor at my urging and was diagnosed 

with endometrial cancer.” 

One of her aunts, who had already had 

multiple primary cancers, sought genetic 

testing in order to serve as a sort of baseline 

for the family. The results have helped others 

in the family become more aware of their risk. 

Desiree herself had experienced reproductive 

health issues throughout her adult life, 

and her doctors thought she might never 

be able to have children. She beat the 

odds, becoming a mother of two. After her 

daughters were born, her doctors urged her 

to have a hysterectomy in order to address 

many of her medical challenges. She resisted, 

because at only 34 years old, she wanted 

to avoid very early, surgically-induced, 

menopause. She began to research options 

in the hopes of keeping her ovaries. 

Following the example of her aunt, Desiree 

sought genetic testing. She hoped it might 

reveal that she didn't have an increased 

risk of ovarian cancer. Instead the results 

showed that she had Lynch Syndrome, a 

hereditary condition that causes increased 

risk for many types of cancer, especially 

ovarian, endometrial and colorectal. Rather 

than providing a rationale for keeping her 

ovaries, genetic testing empowered her 

with the resolve she needed to undergo the 

hysterectomy. 

By opting for the surgery, Desiree eliminated 

her chance of getting endometrial and 

cervical cancer, and dramatically reduced 

her risk for ovarian cancer. Because cancer is 

so prevalent in her family, she remembers, 

“being afraid that the surgeon would 

find a malignancy while performing the 

hysterectomy.” She remains vigilant about 

early detection for the gastrointestinal 

cancers for which she remains at high risk. 

Knowing she has Lynch Syndrome has 

changed the way she talks about health with 

her family. She urged her sister to be tested, 

and she intends to have her daughters tested 

when they are old enough. She knows that 

they each have a 50-50 chance of carrying 

the gene for Lynch Syndrome. 

Because of her experience, Desiree provides 

cancer patients empathy and a level of social 

support that makes a lasting impact. “I have 

been on both sides of the equation, so I 

can speak to my patients as an expert and 

as someone who has been where they are. 

It helps them feel more at ease when they 

see that WellStar offers a way to gain some 

measure of control over their cancer risk.” 


Breast Cancer Program 

PROGRAMMATIC 

VIEW 

In the following pages we will share 

updates about our key oncological 

practice areas, including highlights 

from 2015, success metrics, and a 

preview of 2016 expectations. 

• Breast Program 

• Gastrointestinal (GI) Program 

• Genitourinary (GU) Program 

• Thoracic Program 

• GYN Program 

• Survivorship and Support 

Breast cancer is the second leading cause of 

cancer-related death in women, and the most 

prevalent in terms of widespread awareness. 

The WellStar Cancer Network breast cancer 

program is a model in multi-disciplinary 

success, offering: 

• Dedicated breast surgeons, who practice 

state-of-the-art care including less-invasive 

surgery. Our breast surgeons performed 

603 breast surgeries at WellStar facilities 

in 2015. 

• Medical oncologists who provide access 

to advances through chemotherapy, and 

when appropriate, clinical trials. Radiation 

oncologists offering the latest in treatment 

options including accelerated partial breast 

irradiation (APBI)– which allows patients to 

complete their treatment in five days, versus 

the traditional five-to-six week regimen. 

• Cutting-edge digital imaging, including 

dedicated breast MRI and the ability to 

perform minimally invasive image-guided 

breast biopsies. 

• A comprehensive support network for 

cancer patients and their families that 

includes counseling, cosmetic support for 

the side effects of treatment, lymphedema 

prevention and management, and exercise 

programs designed for better health. 

• The most active cancer genetic counseling 

program in Georgia. 

• Tumor conferences: A treatment planning 

approach in which a number of doctors 

from different specialties review and discuss 

a patient's condition and treatment options. 

More than 25% of breast cancer cases 

diagnosed at WellStar are evaluated by a 

tumor conference. 

Multiple studies have demonstrated similar accuracy of needle biopsy as open surgical biopsy 

in the diagnosis of breast lesions, with lower complication rates. Furthermore, women with 

breast cancer diagnosed by needle biopsy are more likely to be treated with a single surgical 

procedure, even after excluding the initial surgical biopsy procedure. This decreases morbidity 

and increases cost effectiveness and patient satisfaction. In CY 2015, 100% of breast cancer 

patients treated at WellStar had a needle biopsy prior to surgical intervention. 

Source: National Quality Forum 


Despite evidence suggesting the role of 

adjuvant endocrine therapy in lowering 

the risk of tumor recurrence, many female 

patients who should be receiving this 

therapy are not. This measure assesses 

whether patients with a certain stage of 

breast cancer (IC through IIIC) and ER/PR+ 

are currently receiving the therapy. There 

are allowable medical, patient and system 

reasons to document instances in which a 

woman with stage IC through IIIC, ER/PR+ 

may not be a candidate for the therapy. 


100 

80 

60 

40 

20 

Hormone Therapy for Hormone 

Receptor Positive Breast Cancer 

0 

93% 

WellStar 

90% 

Benchmark 

Benchmark: NCBC , CP3R Expected Performance 

Hillary Hahm, M.D., Ph.D. 

Breast Sub Committee Chair 

100 

80 

60 

40 

20 

0 

Combination Chemotherapy 

for Hormone Receptor 

Negative Breast Cancer 

100% 


90% 

Benchmark 

Benchmark: CP3R Expected Performance 

There is extensive documentation of the 

benefit of multi-agent chemotherapy in 

women with hormone receptor negative 

breast cancer. Chemotherapy reduces 

the risk of distant disease recurrence and 

death by about one-third. The restriction 

to women under age 70 is because 

this measure is for the purpose of 

provider accountability. There are limited 

data in women over age 70 to guide 

recommendations, and a higher fraction 

of these women have reasons to omit 

chemotherapy, including co-morbidity. 


Lisa Sherman, BSN, RN 

Breast Nurse Navigator 

Sara Owens, BSN, RN 

Breast Nurse Navigator 


Breast Conservation Surgery Rate 

100 

80 

60 

70% 

40 

53% 

20 

0 

WellStar Benchmark 

Benchmark: NAPBC 

Based on multiple prospective 

randomized trials from both the 

United States and Europe which 

have demonstrated equivalent 

results as measured by overall 

patient survival, consensus exists 

that breast conservation treatment 

is an appropriate method of primary 

therapy for the majority of women 

with Stage I and II breast cancer and is 

preferable because it provides survival 

rates equivalent to those of total 

mastectomy and axillary dissection 

while preserving the breast. Additional 

trials have also determined that breast 

conservation treatment is a reasonable 

approach and is generally applicable 

for most women with Stage 0 breast 

cancer (ductal carcinoma in situ or 

DCIS). However, not all patients are 

appropriate candidates for, or select, 

breast conservation treatment. The 

rate of breast conservation surgery 

will vary significantly based on patient 

age, stage of disease, as well as other 

factors, and therefore will also vary 

between institutions based on case 

mix. No ideal or expected rate of 

breast conservation treatment has been 

established, or is implied. 


There is extensive evidence from 

randomized clinical trials demonstrating 

the impact of radiation with breast 

conservation surgery. It reduces the risk 

of local recurrence in the breast and 

may have a small impact on survival. 

The limitation for the purpose of a 

measure for provider accountability to 

women under the age of 70 is because 

of high-level evidence that women 

with small, estrogen receptor positive 

cancer (the majority of women over age 

70 with breast cancer) gain only a very 

small reduction in local recurrence and 

no difference in lifetime mastectomy 

rate and no difference in survival. 


100 

80 

60 

40 

Post Breast Conserving 

Surgery Radiation 

100% 

90% 

20 

0 


Benchmark 



THE CORGAN MEMORIAL LECTURE 

Post Mastectomy Radiation Therapy 

considered or administered in >4 

Positive Lymph Nodes 

100 

80 

60 

100% 

100% 

This year WellStar lost a cherished colleague in the breast 

surgeon Kristin Corgan, M.D. A few months after her passing 

from breast cancer, we founded the Corgan Memorial Lecture 

as a tribute to her exemplary work. The Corgan Memorial 

Lecture was held in the Kennestone Auditorium on October 

15, 2015. The lecture was given by Shawna Willey, M.D., 

vice chairman for clinical affairs for the department of surgery 

at Georgetown University Hospital, and a colleague of 

Dr. Corgan. Dr. Willey's presentation was entitled, “Breast 

Cancer Surgery. What’s New? What’s Not?” More than 100 

physicians, nurses, healthcare staff and community members 

attended the lecture. 

40 

20 

0 


Benchmark: NAPBC 

Benchmark 

There is consensus that post-mastectomy radiation 

should be recommended for women with breast 

cancer and with >=4 positive regional lymph nodes. 

Numerous studies have shown a significant reduction in 

locoregional recurrence rates, disease-free survival rates, 

and even overall survival with this adjuvant therapy. 

QUALITY IMPROVEMENTS 

In 2015, the breast cancer program addressed a serious 

problem by increasing access to diagnostic and treatment 

services for women who previously did not return for biopsy 

after receiving an abnormal mammogram result. It is now the 

policy of WellStar that any patient who receives an abnormal 

mammogram result will confirm a follow-up appointment for 

a biopsy before leaving the imaging center. This improvement 

has been implemented because a study conducted in 2014 

showed patients reporting decreased anxiety levels when 

leaving the mammography visit with an appointment for a 

concrete next step. 


IORT Procedure 

INTRAOPERATIVE RADIATION THERAPY (IORT) 

In April 2015, WellStar Kennestone started its Intraoperative 

Radiation Therapy (IORT) Pilot Program for early-stage 

breast cancer. IORT allows for delivery of a single fraction 

of radiation to the lumpectomy site while the patient is still 

in the operating room. The use of IORT has been reported 

in two European studies. The ELIOT trial, published by 

Veronesi in 2008, reported the results of 1,246 patients 

treated with intraoperative electron beam radiotherapy 

showing a five-year survival of approximately 96.5 percent. 

The current standard treatment for early-stage breast 

cancer is mastectomy or lumpectomy followed by five to 

seven weeks of daily whole breast radiation therapy (WBRT) 

treatments. Patients for whom IORT is a suitable option are 

no longer inconvenienced by a five- to seven-week schedule 

of daily post-operative WBRT and its possible side effects. 

IORT is well tolerated by patients and is usually performed 

in an outpatient surgery setting. The cosmetic results for 

IORT are favorable, as the radiation is localized to only the 

lumpectomy site. In addition to the clinical and physical 

benefits, IORT is predicted to reduce the overall cost of 

treatment for early-stage breast cancer. 

Tumor is removed. 

Balloon applicator is 

placed into the cavity. 

Radiation treatment 

is delivered in as little 

as 8 minutes. 

Balloon is removed and 

the cavity is closed. 


LYMPHEDEMA 

Lymphedema is a common side effect of breast cancer therapies 

that can have a significant impact on the lives of affected patients. 

Changes in the lymphatic system can cause patients painful 

swelling in the arm, greatly impacting their quality of life as 

well as physical appearance. WellStar's providers recognize the 

importance of early detection and timely interventions as part 

of our overall commitment to care. Therefore in April 2015, we 

launched a multidisciplinary initiative to study ways to identify and 

manage patients with lymphedema at a subclinical stage, with the 

objective of preventing when possible the onset of irreversible 

stages of lymphedema. 


Gastrointestinal (GI) Cancer Program 

Gastrointestinal (GI) cancers include those 

affecting the stomach, pancreas, colon, 

liver and other organs and tissues related 

to digestion. We have a dedicated multidisciplinary 

team of health professionals 

who specialize in treating GI cancers. 

Our GI team works to develop a highly 

customized comprehensive treatment plan 

for each patient that emphasizes efficiency 

and quality of life along with medicine. 

2015 was a year of great achievements for 

the GI program, highlighted by a group of 

WellStar-affiliated physicians presenting at 

the American Society of Clinical Oncology 

(ASCO) Annual Meeting. 

PHBM PROGRAM 

The WellStar Pancreatic Hepatobiliary 

Malignancy (PHBM) Program treats people 

with pancreatic, bile duct and liver cancers. 

The program connects people being treated 

in communities far from our home base 

of metro Atlanta with our state-of-the-art 

therapies and facilities. When a patient 

is first referred, he or she meets with one 

of our nurse navigators, who develop a 

care plan that coordinates the work of the 

treating oncologist, gastroenterologist, 

laboratories, radiation oncologist and other 

specialties as needed. The Nurse Navigator 

can arrange appointments in an effort to 

speed the process of diagnosis and staging 

to first treatment, and reduce the anxiety of 

waiting time between visits. This program 

also allows patients from outside metro 

Atlanta to be treated at WellStar and then 

heal in their home community – truly making 

us a destination cancer center. Patients 

can also opt to have the nurse navigators 

coordinate care to be delivered in the home 

community at a satellite location. Learn more 

about PHBM at wellstar.org/PHBM. 

AMERICAN SOCIETY OF 

CLINICAL ONCOLOGY (ASCO) 

For the cancer research community, there is 

no bigger or more credible stage than the 

ASCO Annual Meeting, which brings tens 

of thousands of cancer experts together 

from around the world. In 2015, a group 

of physicians and nurses from WellStar 

presented a poster session on their study 

entitled Development of a Multidisciplinary 

Program for Evaluation and Treatment 

of Pancreatic Cancer in a Community 

Healthcare System. They studied the efficacy 

of WellStar's approach to staging and 

treating pancreatic cancer, and found that 

our way led to improvements in several key 

areas, including the most important one: 

treatment outcomes. 

QUALITY IMPROVEMENTS 

Understanding the genetic markings 

of a tumor makes it easier to prescribe 

a chemotherapy regimen that has the 

best chance of success for the specific 

type of cancer. For this reason we began 

universal screening for Lynch Syndrome 

on all colorectal and endometrial 

tumor specimens. Lynch Syndrome is 

a hereditary disorder that increases a 

person's risk for colorectal and several 

other forms of cancer, such as stomach, 

liver and ovarian. Leave room for a few 

extra sentences about how cases are 

treated differently if the patient tests 

positive for Lynch Syndrome. Leave 

room for a few extra sentences about 

how cases are treated differently if 

the patient tests positive for Lynch 

Syndrome. 


12 Regional Lymph Nodes 

Removed for 

Resected Colon Cancer 

Adjuvant Chemotherapy for 

Stage III Colon Cancer 

100 

80 

60 

94% 

85% 

100 

80 

60 

93% 

90% 

40 

40 

20 

20 

0 


Benchmark 

0 


Benchmark 



The American College of Pathologists recommended that 

a minimum of 12 lymph nodes be examined to accurately 

identify AJCC stage III colon cancer. 


Evidence that chemotherapy reduces the risk of distant 

disease recurrence and death in persons with nodepositive 

(Stage III) colon cancer. 


100 

80 

60 

40 

90-Day Mortality Following 

Pancreatic Cancer Surgery 

In the modern era, a 2%, 

30-day mortality can be 

expected at high-volume 

centers, and can be as high 

as 7% for 90-day mortality 

outcomes. 

20 

0 

0% 


7% 

Benchmark 


WellStar performed 314 

surgeries and 240 cases 

were presented at tumor 

conference. 

Sahir Shroff, M.D. 

Gastrointestinal Sub 

Committee Chair 

Nancy Page, RN 

Gastrointestinal Cancer 

Nurse Navigator 


Genitourinary (GU) Cancer Program 

The Genitourinary (GU) Program diagnoses 

and treats a wide range of cancers, such as 

prostate, bladder, uterer and kidney. The 

WellStar team serves patients with these 

diseases with a combination of the latest 

research, diagnostic and treatment options, 

including da Vinci Robot surgery, Intensity 

Modulated Radiation Therapy (IMRT), and 

clinical trials. Our highly collaborative multidisciplinary 

team also convenes twice each 

month to discuss cases and craft personalized 

treatment plans. 

ACHIEVEMENTS 

In 2015, WellStar introduced our 

multidisciplinary clinic for prostate cancer 

patients. Our goal is to improve access 

to the highest quality care by removing 

barriers to all treatment options that a man 

may consider. It is the only clinic of its kind 

in Atlanta. With our surgeons, radiation 

oncologists and nurse navigators in one 

location, men do not need to spend valuable 

time going to multiple offices to learn 

about all of their options. WellStar patients 

can access all available information about 

their options in a convenient and easy way. 

They meet with all specialists - our robotic 

surgeons, radiation specialists and others 

– so they can make informed decisions 

more quickly. This can cut down anxiety 

by accelerating the time from diagnosis to 

(Above, l-r) Justin Watson, M.D. and Justin Hart, M.D., Genitourinary Sub Committee Co-Chairs, 

and Michelle Guibault, BS, RN, Genitourinary Oncology Nurse Navigator 

treatment. Once the patient has gathered 

all information, he meets with a nurse 

navigator who helps make decisions about 

treatments, seeks a second opinion on 

pathology if requested, answers questions, 

clarifies options and charts a path forward. 

The WellStar Medical Group Urology practice 

also instituted a change in diagnostic 

approach in 2015, resulting in far fewer 

unnecessary biopsies. This move spared many 

of our patients an uncomfortable, invasive 

procedure and raising the proportion of 

malignancies we diagnose above the national 

average. WellStar's new process is more 

selective when deciding if the patient needs a 

biopsy. We performed 695 prostate biopsies in 

2015 and diagnosed 365 cases of cancer. 


QUALITY METRICS 

i. Number of surgeries: 492 

ii. Number of robotic surgeries: 241. WellStar's GU program is home to three very experienced 

high volume robotic surgeons in Drs. Nikolas Symbas, Thomas Chun, and Justin Watson. 

Dr. Watson is also a fellowship-trained robotic and laparoscopic surgeon, of which there 

are very few in metro Atlanta. Data show significantly better outcomes when a high-volume 

robotic surgeon treats prostate and kidney cancer. 

1. Robotic assisted laparoscopic prostatectomy and lymphadenectomy (185/192 = 96.4%) 

2. Robotic assisted laparoscopic (RAL) partial nephrectomy for kidney cancer (32/42 = 78.6%) 

Justin Hart, M.D. 

Genitourinary Sub 

Committee Co-Chair 

3. Partial cystectomy (for bladder cancer) (42/133 = 31.6%) 

iii. Percentage of operative blood loss less than 400 mL. Under 400 there is no need for transfusion. 

Over that level, a transfusion may be needed. 89.1% 

iv. Percentage of patients on active surveillance 24.2% 

v. Percentage of patients receiving 3D-CRT or IMRT – 100%. 

LOOKING AHEAD 

Prostate cancer is often asymptomatic 

until it has grown and/or spread beyond 

the prostate to a less treatable stage. 

Therefore diagnosing as early as possible is 

of paramount importance. However, there 

are several accepted diagnostic tests which 

look for different indicators of the disease, 

occasionally leading to significant clinical 

uncertainty. Fusion, or multiparametric MRI, 

aims to improve this situation. At WellStar, 

Scott Earley, M.D., and Stu Resnick, M.D., 

head an effort that allows doctors to image 

the prostate in high resolution using a 

highly accurate three-layered MRI. This new 

technique has applications in both planning 

surgery and making a diagnosis. It makes 

possible the detection of occult high grade 

cancers, particularly in those patients who 

have previously undergone a negative 

prostate biopsy, but have a rising prostate 

specific antigen (PSA) level. 

Justin Watson, M.D. 

Genitourinary Sub 

Committee Co-Chair 

Michelle Guibault, BSN, RN 

Genitourinary Oncology 



Thoracic Cancer Program 

ACHIEVEMENTS 

The thoracic program has made remarkable 

progress in several areas, particularly in lung 

cancer screening and treatment. WellStar is 

home to a very active lung screening program, 

which in 2015 screened 1,500 patients. This 

was a noteworthy increase, as the average 

number of patients screened in previous years 

was 200-300 per year. 

The benefit of screening for high-risk patients 

has been what WellStar Chief Surgical Officer, 

William Mayfield, M.D., calls a “stage shift.” 

He explains that about 75% of patients who 

are diagnosed with lung cancer on the basis 

of presenting with symptoms, as opposed to 

having been screened, are at either stage 3 

or 4 at the time of diagnosis. Whereas among 

those who are identified as high risk and are 

screened for lung cancer, 75% of the cases are 

stages I or II at the time of diagnosis. Lung 

cancer generally has a very poor prognosis, 

and is more treatable when caught earlier, 

so this is a truly significant shift. 

In terms of treatment, the thoracic program 

has successfully reduced the amount of time 

from initial abnormal test result to initial 

treatment, thanks to WellStar's STAT (Specialty 

Teams and Treatments) Clinics. Typically, a 

newly diagnosed lung cancer patient might 

wait between 50 and 60 days from the 

time of an abnormal X-ray until his or her 

first treatment, and would be compelled to 

have multiple appointments with different 

providers during that interminable 

wait. WellStar STAT Clinics have 

compressed this timeline to less 

than two weeks. This method 

has been shown to provide faster 

treatment at a lower price with 

better outcomes. Survival rates by 

stage have improved for patients 

treated in this environment, and 

now exceed the SEER database 

averages. 

procedures in the community setting. EBUS 

is a highly effective, minimally invasive biopsy 

that is guided with an ultrasound, so that the 

doctor can focus on specific tissue samples 

and areas of the airways and lungs that look 

irregular. EBUS procedures greatly increase the 

speed and accuracy with which our physicians 

can diagnose and stage lung cancer. WellStar's 

STAT Clinics offer EBUS to improve patient 

experience in several ways: it saves a trip 

to an additional provider; it speeds time to 

treatment; and it causes the patient to miss 

less work, school and other activities. The 

faster diagnosis and staging can also reduce 

anxiety. EBUS is available at Cobb, Douglas 

and Kennestone hospitals. 

Clinical research is very active within the 

Thoracic Cancer Program. Led by Daniel 

L. Miller, M.D., patients are currently being 

enrolled in two national, minimally invasive 

(VATS) studies improving quality outcomes of 

patients undergoing VATS lung cancer surgery. 

More than 97% of our patients with early stage 

disease undergo surgery via a VATS approach. 

William Mayfield, M.D. 

Thoracic Sub 

Committee Chair 

GiGi Bellamy, BSN, RN 

Thoracic Oncology 


Another way that WellStar's 

approach speeds the process from 

initial diagnosis to treatment is by 

having a pulmonologist perform 

Endobronchial Ultrasound (EBUS) 


QUALITY METRICS 

i. Number of surgeries: 182 

ii. Percentage of Stage I, II, and III patients that are seen in STAT Clinic: 53.2% 

iii. Average & median number of pack years – median 40 years, average 46.97 years 

Surgery Not the First Course of 

Treatment for cN2 Lung Cancer 

Systemic Therapy Following 

Surgery for Lymph Node 

Positive Lung Cases 

100 

100 

80 

60 

90.5% 

85% 

80 

60 

90% 

85% 

40 

40 

20 

20 

0 


Benchmark 

0 


Benchmark 



Only 20% of patients with non–small-cell lung cancer 

(NSCLC) present with early-stage disease, which has been 

traditionally treated with surgical resection alone. In patients 

with stage IIIA disease, the role of surgery is significantly 

more complicated. Patients with stage III disease are at 

higher risk for occult metastatic disease and local disease 

progression, and treatment paradigms must include 

therapies that provide both local and distant disease control. 

Adjuvant chemotherapy is the standard of care in 

patients with completely resected stage II and III NSCLC. 

Generally, the absolute OS benefit with chemotherapy at 

five years has been 4%–15% with the most recent metaanalyses 

showing a 4%–5% benefit across all stages. 

Source: American College of Radiology 

Source: American College of Radiology 


THORACIC CANCER PROGRAM 

LOOKING AHEAD 

Buoyed by this proven success, the thoracic 

program has established a STAT Clinic 

at WellStar Douglas Hospital and added 

additional STAT Clinic days at both Cobb and 

Kennestone hospitals. These additions will 

increase capacity to see 40 additional patients 

per week. 

The thoracic program received a grant to fund 

a clinical trial for a breathalyzer test to detect 

lung cancer. It correlates lung cancer screening 

biopsies with breath tests. The ultimate goal of 

this research is to use breathalyzer tests instead 

of X-rays to detect lung cancer. 

Ribbon cutting at the STAT Clinic at WellStar Douglas Hopsital 


Looking Ahead: 

GYN Cancer Program 

In recent years, our physicians noted a 

growing number of patients coming to 

WellStar seeking treatment for gynecological 

cancers, including cervical, endometrial 

and ovarian. To address this need, we have 

planned a multidisciplinary subcommittee 

to be led by Jeffery Hines, M.D., and Amy 

Carroll, M.D. The subcommittee will meet 

quarterly at WellStar Cobb Hospital and will 

include representatives from each discipline 

that treats gynecological cancer. A priority of 

this group will be assigning a nurse navigator 

who will assess needs and develop programs 

and services to meet the specific needs of 

this population of our patients. 

Jeffrey Hines, M.D. 

Gynecologic Oncology 

Sub Committee Chair 

Amy Carroll, M.D. 

Gynecologic Oncologist 


Survivorship & Support Program 

BEHAVIORAL HEALTH TEAM 

As programming and patient volume for 

Cancer Survivorship and Support have 

grown, it was recognized that a greater 

diversity and complexity of service was 

required to meet the behavioral health 

needs of our patients. In the fall of 2015, 

we launched a collaborative approach 

to expand our services to include both a 

psychologist and a psychiatrist. Patients 

who are already in distress and seeing 

multiple providers can now have a wide 

variety of their emotional and psychiatric 

needs met through exposure to two highly 

trained experts in one location. WellStar's 

service is now on par with that of many 

major cancer centers. 

Jennifer Kilkus, Ph.D. 

Clinical Psychologist 

Kajal Patel, M.D. 

General Psychiatry and 

Psychosomatic Medicine 

Psychiatrist 

Physicians can make referrals through 

EPIC, our electronic medical records system, 

or by contacting WellStar Psychological 

Services. We know that oncology patients 

touch many areas in the WellStar system 

and one of our major goals is for primary 

care physicians and other specialists to 

rely on this program as a resource. For that 

reason, any physician, not just oncologists, 

can refer patients to the behavioral health 

team and patients can self-refer. 

The new team approach is an enhancement 

to our already thriving Psycho-oncology 

Program. A total of 1,461 cancer patients 

were screened for psychosocial distress in 

2015. Twelve percent of those screened 

were referred for additional services. 

PATIENT IMPROVEMENTS 

With this team approach, patients 

are now able to be appropriately 

referred to a full-time psychologist 

or psychiatrist with minimal waiting 

time, a significant improvement 

from disjointed community care 

with wait times of up to six weeks 

for new patients. Referrals from 

physicians across the WellStar 

system increased dramatically, 

ensuring that those patients 

who are not identified through 

psychosocial distress screening are accessing 

care through other points in the system. We 

hope to continue to expand services as 

the WellStar Cancer Network grows. 

EDUCATIONAL OPPORTUNITY 

Seeking to replace a discontinued 

Oncology Nursing Society chemotherapy/ 

biotherapy course for nurses, the WellStar 

Oncology Clinical Action Team (WOCAT) 

introduced a new instructor-led course on 

readiness and safety to keep our nurses 

at the leading edge of their profession. 

The course prepares our nurses to test 

for 15 educational hours from the ONS. 

In order to deliver the course and qualify 

our nurses for credit, WellStar became 

an accredited approver of the American 

Nurses Credentialing Center’s Commission 

on Accreditation and an approved provider 

of continuing nursing education by the 

Alabama State Nurses Association. 

The Oncology Nursing Readiness and 

Safety (ONRS) course is taught by WOCAT 

chair, Barbara Wilson, MS, RN, AOCN, 

ACNS-BC, in collaboration with Bethany 

Roberts, DNP, CNM. By the end of 2015, 

the course had been offered three times 

and 59 nurses had successfully completed 

it and earned the credit hours. 


This support group is for patients, family members, caregivers and friends. Participants have the opportunity to share experiences, 

learn about community resources and get the latest information. 

2015 Support Group Participation 

Total Number 

of Participants Meeting 

Group Name (annually) Frequency 

Prostate Cancer Support Group 156 Monthly 

Gastrointestinal Cancer Support Group 51 Monthly 

Breast Cancer Support Group 53 Monthly 

STAR - Cobb Hospital 240 Monthly 

Paulding Cancer Support Group 45 Pilot project: Weekly (9/15-12/15) 

Ostomy Support Group 61 Monthly 

Prostate Cancer 

Support Group 

Prostate Cancer 

Survivors’ Support Group 

Wellness Studio at WellStar 

Kennestone Hospital Cancer Center 

320 Kennestone Hospital Blvd 

Marietta, GA 30060 

Second Thursday of every month 

from 7 p.m.–8 p.m. 

FREE parking available. 

For more information or to RSVP, 

call the WellStar Cancer Connect Line 

at 1-877-366-6032, option 0. 

wellstar.org 

2016 DATES: 

January 14 

February 11 

March 10 

April 14 

May 12 

June 9 

July 14 

August 11 

September 8 

October 13 

November 10 

December 8 

Featuring: 

• Guest speakers 

• Special programs 

• Educational opportunities 

• Community resources 

Thi support group is for patients, family members, caregivers and friends. Participants have the opportunity to share experiences, 

learn about community resources and ge the latest information. 

Breast Cancer 

Support Group 

Breast Cancer Group 

Learning, Sharing, Caring 

Wellness Studio at WellStar 

Kennestone Hospital Cancer Center 



Third Tuesday of every month 

from 6 p.m.–7 p.m. 




at 1-877-366-6032, option 0. 

1/16 CNC0122 


January 19 July 19 

February 16 August 16 

March 15 September 20 

April 19 October 18 

May 17 November 15 

June 21 December 13 

Featuring: 





wellstar.org 

GI Cancer 

Support Group 

Gastrointestinal Cancer Group 

Learning, Sharing, Caring 

Center for Survivorship and Support 

WellStar Kennestone Hospital Cancer Center 



Third Thursday of every month 

from 10 a.m.–11 a.m. 




at 1-877-366-6032, option 0. 

Colon, rectal, pancreas, 

liver, stomach, biliary 

or esophageal cancers 

January 21 

February 18 

March 17 

April 21 

May 19 

June 16 


July 21 

August 18 

September 15 

October 20 

November 17 

December 15 

Featuring: 





Thi support group is for patients, family members, caregivers and friends. Participants have the opportunity to share experiences, 

learn about community resources and ge the latest information. 

1/16 CNC0123 

wellstar.org 

1/16 CNC0121 

Many WellStar providers are leaders in their 

respective fields, whose research and clinical 

work helps define new standards. Clinical 

Psychologist, Jennifer Kilkus, Ph.D., conducted 

a study in 2015 to determine psychological 

factors associated with cancer treatment 

decision making. She will present her work 

at the International Psychosocial Oncology 

Society’s 2016 meeting in Dublin, Ireland. 

A brief summary of the research is below: 

Increase in patient participation in decision 

making has led to a shift toward a collaborative 

approach to treatment communication. 

However, little is known about each patient’s 

preferred role in the treatment decision 

making (TDM) process and the impact of 

the discrepancy between preferred and 

actual role. We measured distress, quality of 

life (QOL), and TDM preference as part of 

a larger study of cancer patients in a nonprofit 

hospital system. Thirty-three percent of 

patients reported a wish to be active in the 

TDM process, 60% preferred a shared role 

with their physician and 7% preferred a passive 

role. When asked their perception of their 

actual role during their last treatment decision, 

28% reported an active role, 49% shared 

and 23% passive. There were no significant 

differences on distress or QOL scores between 

those whose preference matched their actual 

role and those that didn’t. More participants 

reported a shared or passive role than desired 

during their last treatment decision. This may 

impact other aspects of care and survivorship, 

such as satisfaction, decisional regret or future 

treatment decisions. Future research should 

investigate the relationship between TDM role 

and other aspects of the cancer experience. 

Dr. Kilkus hopes to continue her work by 

investigating other aspects of the treatment 

decision making experience of patients being 

treated through the Cancer Network. She 

hopes to examine differences in psychosocial 

outcomes between patients who are involved 

with Center for Survivorship and Support and 

those that are not. 

The newly opened Center for Survivorship 

and Support is a space that is integrated into 

the new 100,000 square-foot WellStar Cancer 

Center at Kennestone Hospital. It is home to 

our nurse navigators, specializing in breast, 

thoracic, gastrointestinal, gynecological and 

urological cancers. These navigators are 

available to patients and their families from 

diagnosis through treatment and beyond, 

helping with: 

• Understanding their diagnosis 

• Providing educational materials and 

resources here and in the community 

• Identifying questions to ask their 

healthcare provider 

• Linking them to care specialists as they 

move through their treatment plan 

Here you’ll also find an oncology social 

worker, who can assist with financial 

concerns, community resources and 

adjustment to diagnosis. The registered 

dietitian can provide individual nutrition 

counseling, personalized meal plans, tube 

feeding management and occasional 

cooking demonstrations. 


A Word About the WellStar Foundation 

WellStar is the largest not-for-profit healthcare provider in Georgia. As such, our physicians’ 

ability to treat patients with the latest technologies and techniques, as well as our leading-edge, 

patient-centered facilities and initiatives, is made possible by support from generous individuals 

and organizations. The WellStar Foundation has been at the forefront of securing these life-saving 

resources for 20 years. 

WellStar’s evolution into a nationally recognized cancer program is ongoing, but in the relationship 

between the Health System and the Foundation, our community roots shine through in the most 

wonderful ways. In fiscal year 2015, the Foundation supported the WellStar Cancer Network with 

more than $3,000,000. These funds – primarily donations to the Foundation from community 

members and grateful families – have provided a number of upgrades that contribute greatly to 

our exceptional patient and survivorship experience as well as our overall results. These include: 

• Resource Center – Dana and David Parks 

• Manning Wellness Kitchen – Judy and Aymar Manning 

• Gray Family Chapel – Northwest Georgia Oncology honoring the life of Dr. Rick Gray 

• Wellness Studio classes – Team Member Giving and Grateful Patients 

• Garden of Courage renovations – WellStar Kennestone Hospital Tower 

and Church Bistro Employees 


The WellStar Cancer Network and the WellStar Foundation sincerely thank the following donors, 

who each gave at least $5,000 to our oncology program in 2015. 

• Jeffrey A. Cox 

• Kellie L. Cox 

• East-West Church 

• It’s The Journey, Inc. 

• National Breast Cancer Foundation 

• Northwest Georgia Oncology Centers, P.C. 

• Susan G. Komen Greater Atlanta 

• WellStar Kennestone Hospital Tower and Church Bistro Employees 

The WellStar Cancer Network would also like to thank the countless donors who provided support 

to the program at any level in 2015. Your generosity assists tremendously in providing the level of 

care and service to our community that sets the standard in our field. 

If you would like to make a donation to the 

WellStar Cancer Network, call the WellStar Foundation 

at 770-956-GIVE (4483) or visit wellstar.org/give. 


wellstar.org 

# • WELLSTAR CANCER NETWORK • 2016 ANNUAL REPORT 12/16 CNC0180

WellStar Cancer Network 2016 Annual Report

Create successful ePaper yourself

Delete template?

Save as template?